As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Kiora Pharmaceuticals, Inc. The largest reported stake is Nantahala Capital Management, LLC's, at 9.99%. 13 filings are on record since August 13, 2025 (Schedule 13G/A, August 14, 2026).
Sell to companies like Kiora Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Baselake Partners, LP · Sole voting: 0 · Shared voting: 257,500 · Sole dispositive: 0 · Shared dispositive: 257,500 · SCHEDULE 13G, 2026-09-17
- · Reporting person: Nantahala Capital Management, LLC · Sole voting: 0 · Shared voting: 491,889 · Sole dispositive: 0 · Shared dispositive: 491,889 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: ADAR1 Capital Management, LLC · Sole voting: 0 · Shared voting: 472,721 · Sole dispositive: 0 · Shared dispositive: 472,721 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Perceptive Advisors LLC · Sole voting: 0 · Shared voting: 442,387 · Sole dispositive: 0 · Shared dispositive: 442,387 · SCHEDULE 13G, 2026-08-10
- · Holder: Nantahala Capital Partners Limited Partnership · Percent: 3.39% · SCHEDULE 13G/A
Kiora Pharmaceuticals, Inc. has 13 Schedule 13D or 13G filings on record since 2025-08-13. 6 holders' latest filing reports 5% or more of common stock, $0.01 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 9.99% | 491,889 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Alyeska Investment Group, L.P. | 9.99% | 394,668 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Perceptive Advisors LLC | 9.99% | 442,387 | SCHEDULE 13G, 2026-08-10 | 2026-04-06 |
| Rosalind Advisors, Inc. | 9.9% | 464,676 | SCHEDULE 13G/A, 2026-02-11 | 2025-12-31 |
| ADAR1 Capital Management, LLC | 9.9% | 472,721 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Baselake Partners, LP | 5.8% | 257,500 | SCHEDULE 13G, 2026-09-17 | 2026-09-10 |
| 4.9% | 192,984 | SCHEDULE 13G/A, 2026-01-29 | 2025-12-31 | |
| Nantahala Capital Partners Limited Partnership | 3.39% | 148,736 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
Holding shares or following this stake? See who's behind Kiora Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Kiora Pharmaceuticals, Inc. and the records around it.
Kiora Pharmaceuticals, Inc. elsewhere on the record
- Leadership changes Sep 2026
- Company profile and every filing Apr 2026
- Form D filing Apr 2026
- Who owns it
Companies that share a holder
- NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP also filed stake reports on 6 other companies: FEMASYS INC. (Aug 2026), AZITRA, INC. (Aug 2026), ABEONA THERAPEUTICS INC. (May 2026)
- Baselake Partners, LP also filed stake reports on 7 other companies: Passage Bio, Inc. (Jun 2026), Generation Bio Co. (Feb 2026), Athira Pharma, Inc. (Feb 2026)
- Rosalind Advisors, Inc. also filed stake reports on 11 other companies: DELCATH SYSTEMS, INC. (Oct 2026), FEMASYS INC (Aug 2026), FENNEC PHARMACEUTICALS INC. (Aug 2026)
Watch Kiora Pharmaceuticals, Inc.
Get an email when Kiora Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Kiora Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Kiora Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kiora Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 0 | 491,889 | 0 | 491,889 | SCHEDULE 13G/A, 2026-08-14 |
| Wilmot B. Harkey | 0 | 491,889 | 0 | 491,889 | SCHEDULE 13G/A, 2026-08-14 |
| Daniel Mack | 0 | 491,889 | 0 | 491,889 | SCHEDULE 13G/A, 2026-08-14 |
| Perceptive Advisors LLC | 0 | 442,387 | 0 | 442,387 | SCHEDULE 13G, 2026-08-10 |
| Joseph Edelman | 0 | 442,387 | 0 | 442,387 | SCHEDULE 13G, 2026-08-10 |
| Perceptive Life Sciences Master Fund, Ltd. | 0 | 442,387 | 0 | 442,387 | SCHEDULE 13G, 2026-08-10 |
| ADAR1 Capital Management, LLC | 0 | 472,721 | 0 | 472,721 | SCHEDULE 13G/A, 2026-08-14 |
| ADAR1 Capital Management GP, LLC | 0 | 475,378 | 0 | 475,378 | SCHEDULE 13G/A, 2026-08-14 |
| Daniel Schneeberger | 0 | 472,721 | 0 | 472,721 | SCHEDULE 13G/A, 2026-08-14 |
| Baselake Partners, LP | 0 | 257,500 | 0 | 257,500 | SCHEDULE 13G, 2026-09-17 |
| Baselake Management, LLC | 0 | 257,500 | 0 | 257,500 | SCHEDULE 13G, 2026-09-17 |
| David Paolella | 0 | 257,500 | 0 | 257,500 | SCHEDULE 13G, 2026-09-17 |
The latest filing identifies Kiora Pharmaceuticals, Inc. by CUSIP 49721T507 and gives its principal executive office as 169 Saxony Rd., Suite 212, Encinitas, CA 92024 (SCHEDULE 13G, 2026-09-17).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-13 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
| 2025-08-14 | Nantahala Capital Partners Limited Partnership | 5.3% | SCHEDULE 13G |
| 2025-08-14 | ADAR1 Capital Management, LLC | 9.9% | SCHEDULE 13G/A |
| 2025-11-14 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-01-29 | Orin Hirschman | 4.9% | SCHEDULE 13G/A |
| 2026-02-11 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
| 2026-05-15 | Nantahala Capital Partners Limited Partnership | 3.39% | SCHEDULE 13G/A |
| 2026-05-15 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-05-15 | Alyeska Investment Group, L.P. | 9.99% | SCHEDULE 13G |
| 2026-08-10 | Perceptive Advisors LLC | 9.99% | SCHEDULE 13G |
| 2026-08-14 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-08-14 | ADAR1 Capital Management, LLC | 9.9% | SCHEDULE 13G/A |
| 2026-09-17 | Baselake Partners, LP | 5.8% | SCHEDULE 13G |
Questions about who owns Kiora Pharmaceuticals, Inc.
Who owns Kiora Pharmaceuticals, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Kiora Pharmaceuticals, Inc.: Nantahala Capital Management, LLC (9.99%, Schedule 13G/A, filed 2026-08-14), Alyeska Investment Group, L.P. (9.99%, Schedule 13G, filed 2026-05-15), Perceptive Advisors LLC (9.99%, Schedule 13G, filed 2026-08-10), Rosalind Advisors, Inc. (9.9%, Schedule 13G/A, filed 2026-02-11) and ADAR1 Capital Management, LLC (9.9%, Schedule 13G/A, filed 2026-08-14); 1 more is listed above.
Who are the largest shareholders of Kiora Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Kiora Pharmaceuticals, Inc. on this page are Nantahala Capital Management, LLC (9.99%), Alyeska Investment Group, L.P. (9.99%) and Perceptive Advisors LLC (9.99%).
When did Nantahala Capital Management, LLC buy into Kiora Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Nantahala Capital Management, LLC on this page is the Schedule 13G/A, filed 2025-11-14, reporting 9.99%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Kiora Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 8, 2026 | Leadership change: Keith Lane appointed, Executive Vice President, Head | — | Leadership changes | Source |
| April 21, 2026 | Form D, private offering | $5M sold | Form D page | Source |
| April 2, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Kiora Pharmaceuticals, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Kiora Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.